Heatwurx (PCSA) Stock Price, News & Analysis

Company Overview

Heatwurx is an asphalt pavement maintenance technology company that develops and markets infrared-based repair systems. Its technology uses controlled heat to soften existing asphalt and enable repairs that integrate new and reclaimed pavement material with the surrounding surface.

The company’s products are designed for applications such as pothole repair, pavement seams, utility cuts, overlays and other localized roadway defects. Heatwurx systems are intended for use by paving contractors, municipalities and other organizations responsible for maintaining asphalt surfaces, with an emphasis on extending pavement life and reducing the need for extensive removal and replacement.

Publicly available information about Heatwurx’s ownership, leadership and geographic operations is limited. In addition, NASDAQ:PCSA is associated with Processa Pharmaceuticals rather than Heatwurx, so the ticker supplied does not appear to correspond to the Heatwurx business.

Key Stats

• Today's Range: $1.04 to $1.87
• 50-Day Range: $1.35 to $2.63
• 52-Week Range: $1.04 to $11.08
• Volume: 2.95 million shs
• Average Volume: 21,733 shs
• Market Capitalization: $4.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Heatwurx Stock Analysis - MarketRank™

Heatwurx scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Heatwurx has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Heatwurx has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Heatwurx is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Heatwurx is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Heatwurx has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.15% of the float of Heatwurx has been sold short.

Short Interest Ratio / Days to Cover

Heatwurx has a short interest ratio ("days to cover") of 0.18, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Heatwurx has recently decreased by 72.39%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Heatwurx does not currently pay a dividend.

Dividend Growth

Heatwurx does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for Heatwurx this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Heatwurx insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.50% of the stock of Heatwurx is held by insiders.

Percentage Held by Institutions

91.93% of the stock of Heatwurx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/10/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:PCSA
• CIK: 1533743
• Web: www.processapharmaceuticals.com
• Phone: (443) 776-3133
• Fax: 443-288-4420
• Employees: 12
• Year Founded: 2017

Profitability

• EPS (Trailing Twelve Months): ($4.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.56 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -394.25%
• Return on Assets: -244.46%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.87
• Quick Ratio: 0.87

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.46 per share
• Price / Book: 0.62

Miscellaneous

• Outstanding Shares: 2,770,000
• Free Float: 2,671,000
• Market Cap: $4.21 million
• Optionable: Not Optionable
• Beta: 1.20